三诺生物公告称，公司于2025年审议通过回购方案，拟以1.5亿元-3亿元自有资金及贷款回购股份，用 于员工持股等，回购价上限调为33.78元/股。截至2026年1月31日，公司累计回购1369.12万股，占总股 本2.44%，最高成交价21.39元/股，最低17.27元/股，成交总金额2.62亿元。公司后续将按规定在期限内 继续实施回购并披露进展。 ...

Core Viewpoint - The ChiNext Medical Index (970082) closed at 3876.07 points on February 3, with a gain of 2.37% and a trading volume of 13.236 billion yuan, indicating positive market sentiment in the medical sector [1]. Group 1: Index Performance - The ChiNext Medical Index saw 49 constituent stocks rise, with NuoSiGe leading the gains at 8.76% [1]. - The index's turnover rate was 1.71%, reflecting moderate trading activity [1]. Group 2: Top Constituents - The top ten constituents of the ChiNext Medical Index include: - YuanEr Eye Hospital (sz300015) with a weight of 9.18% and a latest price of 11.04 yuan, up 1.28% [1]. - MaiRui Medical (sz300760) with a weight of 8.95% and a latest price of 188.15 yuan, up 0.56% [1]. - TaiGe Medical (sz300347) with a weight of 8.52% and a latest price of 63.20 yuan, up 4.97% [1]. - KangLong HuaCheng (sz300759) with a weight of 7.18% and a latest price of 29.61 yuan, up 2.10% [1]. - LePu Medical (sz300003) with a weight of 4.96% and a latest price of 17.83 yuan, up 1.89% [1]. - New Industry (sz300832) with a weight of 4.73% and a latest price of 54.50 yuan, up 2.60% [1]. - AiMeiKe (sz300896) with a weight of 4.49% and a latest price of 147.57 yuan, up 4.56% [1]. - YingKe Medical (sz300677) with a weight of 4.14% and a latest price of 40.55 yuan, up 1.38% [1]. - FuRui Medical (sz300049) with a weight of 3.55% and a latest price of 67.33 yuan, up 1.45% [1]. - HuaDa Gene (sz300676) with a weight of 3.15% and a latest price of 50.30 yuan, up 2.57% [1]. Group 3: Capital Flow - The net inflow of main funds into the ChiNext Medical Index constituents totaled 145 million yuan, while retail investors experienced a net outflow of 106 million yuan [1]. - The detailed capital flow indicates that TaiGe Medical had a main fund net inflow of 10.514 million yuan, while retail investors had a net outflow of 18.28% [2].

Key Points - The report highlights the recent increase in shareholding by major stakeholders in several A-share listed companies, indicating confidence in their long-term value and growth potential [10][12]. - Key companies to focus on include Jintian Copper, Pianzaihuang, and Sanofi Biologics, each demonstrating significant management confidence through share buybacks or increases in shareholding [14][20][26]. Group 1: Jintian Copper - Jintian Copper's controlling shareholder plans to increase holdings by no less than 50 million RMB and no more than 100 million RMB, representing an average of 0.36% of the total market value [11][14]. - The company is a leader in copper and copper alloy materials, with a complete industrial chain and a focus on rare earth permanent magnet materials, serving sectors like new energy vehicles and clean energy [14][16]. - Jintian Copper is also the largest recycler of copper in China, emphasizing its commitment to green and low-carbon development [15][16]. Group 2: Pianzaihuang - Pianzaihuang's controlling shareholder plans to increase holdings by no less than 300 million RMB and no more than 500 million RMB, which is about 0.42% of the total market value [12][20]. - The company specializes in traditional Chinese medicine, with its core product, Pianzaihuang, having a history of nearly 500 years and protected formulation techniques [21][22]. - Pianzaihuang is expanding its product line into liver disease, cold medications, and skincare, while also upgrading its pharmaceutical distribution business [22][23]. Group 3: Sanofi Biologics - The Vice Chairman and General Manager of Sanofi Biologics increased her holdings by 1,017.8 million RMB, representing 0.1% of the total shares [12][26]. - The company focuses on diabetes and chronic disease management, transitioning from single glucose monitoring to a multi-parameter detection system [26]. - Sanofi Biologics has expanded its market presence to 187 countries and regions, developing a comprehensive sales system and innovative healthcare solutions [26].

1月30日，三诺生物跌2.66%，成交额1.66亿元。两融数据显示，当日三诺生物获融资买入额981.66万 元，融资偿还1864.21万元，融资净买入-882.55万元。截至1月30日，三诺生物融资融券余额合计3.67亿 元。 分红方面，三诺生物A股上市后累计派现15.12亿元。近三年，累计派现3.44亿元。 机构持仓方面，截止2025年9月30日，三诺生物十大流通股东中，香港中央结算有限公司位居第三大流 通股东，持股2566.60万股，相比上期增加329.67万股。睿远成长价值混合A（007119）位居第四大流通 股东，持股1832.48万股，相比上期减少873.24万股。华宝中证医疗ETF（512170）位居第六大流通股 东，持股961.42万股，相比上期减少150.68万股。睿远均衡价值三年持有混合A（008969）位居第八大 流通股东，持股610.00万股，相比上期减少690.00万股。 声明：市场有风险，投资需谨慎。本文基于第三方数据库自动发布，不代表新浪财经观点，任何在本文 出现的信息均只作为参考，不构成个人投资建议。如有出入请以实际公告为准。如有疑问，请联系 biz@staff.sina.com ...

Macro and Strategy - In 2025, China's economy is expected to achieve a growth rate of 5.0%, showing a "high first, low later" trend, with a significant inverse relationship between GDP growth and price performance [8][9] - The structural transformation in 2025 is positive, with a decline in the growth rate of the secondary industry and an increase in the tertiary industry, which helps alleviate excess supply pressure and supports domestic demand through service sector development [8][9] - The overall domestic demand remains at a historically low level, with insufficient internal demand being a major bottleneck in the economic cycle [8][9] Chemical Industry - The phosphate chemical industry is characterized by a tight supply-demand balance, with the wet-process phosphoric acid being the core preparation route, gradually replacing the energy-intensive thermal process [28][29] - Domestic phosphate rock supply is tightening due to strict environmental regulations, leading to a significant reduction in outdated production capacity [28][29] - The demand for phosphate rock is expected to remain robust, with the gross profit margin for leading enterprises around 80%, while the share of wet-process phosphoric acid consumption is projected to increase significantly by 2024 [29][30] Electronic Industry - The LCD panel industry has seen an increase in prices, with the panel index rising by 11.55% since December 2025, outperforming major stock indices [31][32] - The global revenue for large-sized LCD panels in December reached $6.423 billion, with a month-on-month growth of 15.52% [32] - Price increases for various sizes of LCD TV panels are expected to continue into February, driven by strong demand from television brands [33] Agricultural Industry - The price of live pigs is expected to continue rising, supported by the "anti-involution" policy, with the price recorded at 12.87 yuan/kg as of January 23, 2026 [36] - The supply of white chickens has slightly increased, with a focus on seasonal consumption recovery, while the price of yellow chickens is expected to benefit from improved domestic demand [36]

| 证券代码：300298 | 证券简称：三诺生物 | 公告编号：2026-010 | | --- | --- | --- | | 债券代码：123090 | 债券简称：三诺转债 | | 三诺生物传感股份有限公司 三诺生物传感股份有限公司（以下简称"公司"）于2026年1月29日收到公 司副董事长兼总经理李心一女士出具的《关于增持公司股份的告知承诺函》，基 于对公司未来持续稳定发展的信心以及对公司长期投资价值的认可，李心一女士 于2026年1月29日以其自有资金通过深圳证券交易所交易系统以集中竞价交易方 式累计增持公司股份571,800股，增持股份占公司总股本的0.10%，占公司总股本 剔除公司回购专用账户中股份后的0.10%。现将具体情况公告如下： 一、增持主体的基本情况 1、增持主体：公司副董事长兼总经理李心一女士。李心一女士同时系公司 控股股东、实际控制人李少波先生的女儿。 2、本次增持前持股情况：本次增持前，李心一女士直接持有公司股份815,800 股，占公司总股本的0.15%，占公司总股本剔除公司回购专用账户股份后的0.15%。 李心一女士及其一致行动人李少波先生合计持有公司股份143,501,44 ...

证券日报网讯1月29日，三诺生物（300298）发布公告称，截至2026年1月29日，公司通过股份回购专用 证券账户以集中竞价交易方式累计回购公司股份11，831，161股，占公司当前总股本的比例为2.11%。 ...

| 证券代码：300298 | 证券简称：三诺生物 | 公告编号：2026-009 | | --- | --- | --- | | 债券代码：123090 | 债券简称：三诺转债 | | 三诺生物传感股份有限公司 关于回购公司部分股份比例达到2%的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 三诺生物传感股份有限公司（以下简称"公司"）于 2025 年 2 月 20 日召开 第五届董事会第十六次会议和第五届监事会第十二次会议，审议并通过《关于回 购公司部分股份方案的议案》，同意公司使用自有资金及银行回购专项贷款以集 中竞价交易的方式回购公司部分社会公众股份，用于员工持股计划、股权激励或 者用于转换上市公司发行的可转换为股票的公司债券。回购资金总额不低于人民 币 15,000 万元且不超过人民币 30,000 万元（均含本数），回购价格不超过人民币 34.00 元/股（含），实施期限为自董事会审议通过本次回购部分股份方案之日起 12 个月内。2025 年 6 月 13 日，公司实施完成 2024 年年度权益分派方案，根据 公司《关于回购公司部分股份方 ...

证券日报网讯 1月28日，三诺生物发布公告称，控股股东李少波将7330000股高管锁定股质押展期至 2027年1月27日，占其持股5.14%，对应公司总股本1.31%，质权人为国泰海通证券股份有限公司，用途 为偿还质押融资。 （文章来源：证券日报） ...

北京商报讯1月28日晚间，三诺生物（300298）发布2025年业绩预告显示，预计2025年实现归属净利润 8500万元至12750万元，比上年同期下降60.92%至73.95%。 三诺生物表示，报告期内，公司全资子公司Polymer Technology Systems,Inc.（以下简称"PTS公司"）经 营业绩未达预期。结合PTS公司实际经营状况、行业市场变化和预期经营情况，经公司根据谨慎性原则 初步判断，对收购PTS公司所形成的商誉计提部分减值，预计本期计提的商誉减值总额为1.3亿元至1.7 亿元。 （文章来源：北京商报） ...